U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07695597) titled 'A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia' on July 06.
Brief Summary: This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.
Study Start Date: July 17
Study Type: INTERVENTIONAL
Condition:
Mixed Hyperlipidemia
Intervention:
DRUG: SYH2070
SYH2070 injection, 150 mg, 300 mg, 400 mg, SC, administration duration: 24 weeks
DRUG: Placebo
Placebo, SC, administration duration: 24 weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiaz...